Smithfield Trust Co Sells 1,490 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Smithfield Trust Co decreased its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 43.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,938 shares of the company’s stock after selling 1,490 shares during the quarter. Smithfield Trust Co’s holdings in Takeda Pharmaceutical were worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in TAK. Versant Capital Management Inc bought a new stake in Takeda Pharmaceutical in the 4th quarter worth approximately $26,000. Wilmington Savings Fund Society FSB bought a new stake in Takeda Pharmaceutical in the 3rd quarter worth approximately $40,000. BNP Paribas Financial Markets increased its stake in Takeda Pharmaceutical by 416.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after acquiring an additional 2,596 shares during the last quarter. Erste Asset Management GmbH bought a new stake in Takeda Pharmaceutical in the 3rd quarter worth approximately $52,000. Finally, Cromwell Holdings LLC bought a new stake in Takeda Pharmaceutical in the 4th quarter worth approximately $61,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $15.06 on Thursday. The company has a market cap of $47.90 billion, a P/E ratio of 37.64, a P/E/G ratio of 0.24 and a beta of 0.46. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The business’s 50 day moving average price is $13.51 and its 200-day moving average price is $13.90. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.